{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T20:35:26Z","timestamp":1791318926414,"version":"4.3.1"},"reference-count":22,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"27","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCO"],"published-print":{"date-parts":[[2008,9,20]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Bendamustine HCl is a bifunctional mechlorethamine derivative with clinical activity in the treatment of non-Hodgkin's lymphoma. This study evaluated bendamustine plus rituximab in 67 adults with relapsed, indolent B-cell or mantle cell lymphoma without documented resistance to prior rituximab.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and Methods<\/jats:title>\n                    <jats:p>\n                      Patients received rituximab 375 mg\/m\n                      <jats:sup>2<\/jats:sup>\n                      intravenously on day 1 and bendamustine 90 mg\/m\n                      <jats:sup>2<\/jats:sup>\n                      intravenously on days 2 and 3 of each 28-day cycle for four to six cycles. An additional dose of rituximab was administered 1 week before the first cycle and 4 weeks after the last cycle. Sixty-six patients (median age, 60 years) received at least one dose of both drugs.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Overall response rate was 92% (41% complete response, 14% unconfirmed complete response, and 38% partial response). Median duration of response was 21 months (95% CI, 18 to 24 months). Median progression-free survival time was 23 months (95% CI, 20 to 26 months). Outcomes were similar for patients with indolent or mantle cell histologies. The combination was generally well tolerated; the primary toxicity was myelosuppression (grade 3 or 4 neutropenia, 36%; grade 3 or 4 thrombocytopenia, 9%).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Bendamustine plus rituximab is an active combination in patients with relapsed indolent and mantle cell lymphoma.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1200\/jco.2008.17.0001","type":"journal-article","created":{"date-parts":[[2008,7,14]],"date-time":"2008-07-14T21:09:36Z","timestamp":1216069776000},"page":"4473-4479","source":"Crossref","is-referenced-by-count":298,"title":["Phase II Multicenter Study of Bendamustine Plus Rituximab in Patients With Relapsed Indolent B-Cell and Mantle Cell Non-Hodgkin's Lymphoma"],"prefix":"10.1200","volume":"26","author":[{"given":"K. Sue","family":"Robinson","sequence":"first","affiliation":[{"name":"From the QE II Health Sciences Centre, Halifax, Nova Scotia; Ottawa General Hospital, Ottawa; Northeastern Ontario Regional Cancer Centre, Sudbury, Ontario; Hospital Notre-Dame Du Chum, Montreal, Quebec, Canada; University of Virginia Health System, Charlottesville, VA; Georgetown University Hospital, Washington, DC; University of Southern California\/Norris Cancer Hospital, Los Angeles, CA; and West Cancer Clinic, Memphis, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael E.","family":"Williams","sequence":"additional","affiliation":[{"name":"From the QE II Health Sciences Centre, Halifax, Nova Scotia; Ottawa General Hospital, Ottawa; Northeastern Ontario Regional Cancer Centre, Sudbury, Ontario; Hospital Notre-Dame Du Chum, Montreal, Quebec, Canada; University of Virginia Health System, Charlottesville, VA; Georgetown University Hospital, Washington, DC; University of Southern California\/Norris Cancer Hospital, Los Angeles, CA; and West Cancer Clinic, Memphis, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard H.","family":"van der Jagt","sequence":"additional","affiliation":[{"name":"From the QE II Health Sciences Centre, Halifax, Nova Scotia; Ottawa General Hospital, Ottawa; Northeastern Ontario Regional Cancer Centre, Sudbury, Ontario; Hospital Notre-Dame Du Chum, Montreal, Quebec, Canada; University of Virginia Health System, Charlottesville, VA; Georgetown University Hospital, Washington, DC; University of Southern California\/Norris Cancer Hospital, Los Angeles, CA; and West Cancer Clinic, Memphis, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Cohen","sequence":"additional","affiliation":[{"name":"From the QE II Health Sciences Centre, Halifax, Nova Scotia; Ottawa General Hospital, Ottawa; Northeastern Ontario Regional Cancer Centre, Sudbury, Ontario; Hospital Notre-Dame Du Chum, Montreal, Quebec, Canada; University of Virginia Health System, Charlottesville, VA; Georgetown University Hospital, Washington, DC; University of Southern California\/Norris Cancer Hospital, Los Angeles, CA; and West Cancer Clinic, Memphis, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordan A.","family":"Herst","sequence":"additional","affiliation":[{"name":"From the QE II Health Sciences Centre, Halifax, Nova Scotia; Ottawa General Hospital, Ottawa; Northeastern Ontario Regional Cancer Centre, Sudbury, Ontario; Hospital Notre-Dame Du Chum, Montreal, Quebec, Canada; University of Virginia Health System, Charlottesville, VA; Georgetown University Hospital, Washington, DC; University of Southern California\/Norris Cancer Hospital, Los Angeles, CA; and West Cancer Clinic, Memphis, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anil","family":"Tulpule","sequence":"additional","affiliation":[{"name":"From the QE II Health Sciences Centre, Halifax, Nova Scotia; Ottawa General Hospital, Ottawa; Northeastern Ontario Regional Cancer Centre, Sudbury, Ontario; Hospital Notre-Dame Du Chum, Montreal, Quebec, Canada; University of Virginia Health System, Charlottesville, VA; Georgetown University Hospital, Washington, DC; University of Southern California\/Norris Cancer Hospital, Los Angeles, CA; and West Cancer Clinic, Memphis, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lee S.","family":"Schwartzberg","sequence":"additional","affiliation":[{"name":"From the QE II Health Sciences Centre, Halifax, Nova Scotia; Ottawa General Hospital, Ottawa; Northeastern Ontario Regional Cancer Centre, Sudbury, Ontario; Hospital Notre-Dame Du Chum, Montreal, Quebec, Canada; University of Virginia Health System, Charlottesville, VA; Georgetown University Hospital, Washington, DC; University of Southern California\/Norris Cancer Hospital, Los Angeles, CA; and West Cancer Clinic, Memphis, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard","family":"Lemieux","sequence":"additional","affiliation":[{"name":"From the QE II Health Sciences Centre, Halifax, Nova Scotia; Ottawa General Hospital, Ottawa; Northeastern Ontario Regional Cancer Centre, Sudbury, Ontario; Hospital Notre-Dame Du Chum, Montreal, Quebec, Canada; University of Virginia Health System, Charlottesville, VA; Georgetown University Hospital, Washington, DC; University of Southern California\/Norris Cancer Hospital, Los Angeles, CA; and West Cancer Clinic, Memphis, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce D.","family":"Cheson","sequence":"additional","affiliation":[{"name":"From the QE II Health Sciences Centre, Halifax, Nova Scotia; Ottawa General Hospital, Ottawa; Northeastern Ontario Regional Cancer Centre, Sudbury, Ontario; Hospital Notre-Dame Du Chum, Montreal, Quebec, Canada; University of Virginia Health System, Charlottesville, VA; Georgetown University Hospital, Washington, DC; University of Southern California\/Norris Cancer Hospital, Los Angeles, CA; and West Cancer Clinic, Memphis, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"R2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djk152"},{"key":"R3","doi-asserted-by":"crossref","unstructured":"Friedberg JW, Huang J, Dillon H, et al: Initial therapeutic strategy in follicular lymphoma (FL): An analysis from the National LymphoCare Study (NLCS). J Clin Oncol 24:428s,2006,  (suppl, abstr 7527)","DOI":"10.1200\/jco.2006.24.18_suppl.7527"},{"key":"R4","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.03.1674"},{"key":"R5","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.12.191"},{"key":"R6","doi-asserted-by":"publisher","DOI":"10.1097\/01.cco.0000174039.69656.2b"},{"key":"R8","doi-asserted-by":"publisher","DOI":"10.1097\/00001813-199606000-00007"},{"key":"R9","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-1061"},{"key":"R10","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.12.5070"},{"key":"R11","unstructured":"Chow KU, Sommerlad WD, Boehrer S, et al: Anti-CD20 antibody (IDEC-C2B8, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: Role of cytokines, complement, and caspases. Haematologica 87:33,2002-43,"},{"key":"R12","unstructured":"Alas S, Emmanouilides C, Bonavida B: Inhibition of interleukin 10 by rituximab results in down-regulation of bcl-2 and sensitization of B-cell non-Hodgkin's lymphoma to apoptosis. Clin Cancer Res 7:709,2001-723,"},{"key":"R14","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.4.1244"},{"key":"R15","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.08.100"},{"key":"R16","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.8.2825"},{"key":"R17","doi-asserted-by":"crossref","unstructured":"Brookmeyer R, Crowley J: A confidence interval for the median survival time. Biometrics 39:29,2007-41,","DOI":"10.2307\/2530286"},{"key":"R18","doi-asserted-by":"publisher","DOI":"10.1080\/10428190400004521"},{"key":"R19","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.11.017"},{"key":"R20","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.07.040"},{"key":"R21","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-05-021113"},{"key":"R22","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-04-1323"},{"key":"R23","doi-asserted-by":"crossref","unstructured":"Rummel MJ, von Grunhagen U, Niederle N, et al: Bendamustine plus rituximab versus CHOP plus rituximab in the first-line treatment of patients with indolent and mantle cell lymphomas: First interim results of a randomized phase III study of the StiL (Study Group Indolent Lymphomas, Germany). Blood 110:385,2007,  (abstr)","DOI":"10.1182\/blood.V110.11.385.385"},{"key":"R24","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-08-3175"},{"key":"R25","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-01-0016"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.2008.17.0001","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T16:18:35Z","timestamp":1653495515000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.2008.17.0001"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,9,20]]},"references-count":22,"journal-issue":{"issue":"27","published-print":{"date-parts":[[2008,9,20]]}},"alternative-id":["10.1200\/JCO.2008.17.0001"],"URL":"https:\/\/doi.org\/10.1200\/jco.2008.17.0001","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.1123857.580953","asserted-by":"object"},{"id-type":"doi","id":"10.3410\/f.1123857.581453","asserted-by":"object"}]},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,9,20]]}}}